SCHEMBL2805800

SCHEMBL2805800

COc1cc(C(=O)NS(=O)(=O)c2ccccc2S(N)(=O)=O)ccc1C#Cc1cccc(Cl)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 2/20 0.68
CPT1A P50416 1/20 0.44
CPT1B Q92523 1/20 0.44
STAT3 P40763 1/20 0.40
KDR P35968 4/20 0.39
FLT1 P17948 2/20 0.39
FLT4 P35916 2/20 0.39
CA12 O43570 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
GAA P10253 1/20 0.39
PKM P14618 1/20 0.39
PTGES2 Q9H7Z7 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
PDGFRB P09619 2/20 0.38
PTGDR2 Q9Y5Y4 2/20 0.38
CYP2C9 P11712 1/20 0.38
P2RX4 Q99571 1/20 0.37
BCL2L1 Q07817 1/20 0.37
MCL1 Q07820 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2802222 0.91 PTGES (0.69) PTGESCPT1ACPT1BSTAT3KDR
SCHEMBL2802112 0.91 PTGES (0.74) PTGESCPT1ACPT1BSTAT3CA12
SCHEMBL2804985 0.90 PTGES (0.70) PTGESCPT1ACPT1BKDRCA12
SCHEMBL2804978 0.89 PTGES (0.68) PTGESCPT1ACPT1BKDRCA12
SCHEMBL2804931 0.87 PTGES (0.70) PTGESCPT1ACPT1BSTAT3CA12
SCHEMBL2803372 0.86 PTGES (0.69) PTGESCA12CA2CA9GAA
SCHEMBL2801478 0.85 PTGES (0.78) PTGESCPT1ACPT1BKDRFLT1
SCHEMBL2803055 0.84 PTGES (0.72) PTGESCA2CA9PKM
SCHEMBL2805040 0.83 PTGES (0.66) PTGESCA12CA2CA9GAA
SCHEMBL980321 0.83 PTGES (0.74) PTGESSTAT3CA12CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO claimed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US claimed
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy PTGER1, SULT2A1, SULT1E1 PTGES 9/4885CPT1A 67/4885CPT1B 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.